Celgene to buy Juno Therapeutics
MLex Summary: Celgene has agreed to buy Juno Therapeutics for $9 billion, in a bid to advance its global leadership in cellular immunotherapy. The transaction is expected to close in the first...To view the full article, register now.
Already a subscriber? Click here to view full article